Spinocerebellar Ataxia Type 6 (SCA6)

Spinocerebellar Ataxia Type 6 (SCA6)

Introduction

Spinocerebellar Ataxia Type 6 (Sca6) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Spinocerebellar Ataxia type 6 (SCA6) is a rare, autosomal dominant, late-onset neurodegenerative disease characterized by slowly progressive cerebellar ataxia, dysarthria, and nystagmus. It is caused by a CAG trinucleotide repeat expansion in the CACNA1A gene on chromosome 19p13.13, which encodes the alpha-1A subunit of P/Q-type voltage-gated calcium channels (Cav2.1). SCA6 is unique among polyglutamine diseases in that the affected protein is a voltage-gated calcium channel subunit, making it simultaneously a channelopathy and a polyglutamine disorder[1](#1). [@cerebellar]

Overview

SCA6 is one of over 40 genetically distinct subtypes of [Spinocerebellar Ataxia](/diseases/spinocerebellar-ataxia). It has a global prevalence of less than 1 per 100,000 individuals, with the highest frequency in Japan where it accounts for up to 31% of all autosomal dominant cerebellar ataxias[2](#1). The disease typically manifests between ages 43 and 52, with a range from 19 to 73 years, and is generally compatible with a normal lifespan, distinguishing it from many other SCAs[3](#1). [@identification]

Spinocerebellar Ataxia Type 6 (SCA6)

Introduction

Spinocerebellar Ataxia Type 6 (Sca6) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Spinocerebellar Ataxia type 6 (SCA6) is a rare, autosomal dominant, late-onset neurodegenerative disease characterized by slowly progressive cerebellar ataxia, dysarthria, and nystagmus. It is caused by a CAG trinucleotide repeat expansion in the CACNA1A gene on chromosome 19p13.13, which encodes the alpha-1A subunit of P/Q-type voltage-gated calcium channels (Cav2.1). SCA6 is unique among polyglutamine diseases in that the affected protein is a voltage-gated calcium channel subunit, making it simultaneously a channelopathy and a polyglutamine disorder[1](#1). [@cerebellar]

Overview

SCA6 is one of over 40 genetically distinct subtypes of [Spinocerebellar Ataxia](/diseases/spinocerebellar-ataxia). It has a global prevalence of less than 1 per 100,000 individuals, with the highest frequency in Japan where it accounts for up to 31% of all autosomal dominant cerebellar ataxias[2](#1). The disease typically manifests between ages 43 and 52, with a range from 19 to 73 years, and is generally compatible with a normal lifespan, distinguishing it from many other SCAs[3](#1). [@identification]

SCA6 is considered the prototype of a "pure" cerebellar ataxia with minimal extra-cerebellar involvement. The neuropathology reveals selective degeneration of [Purkinje cells](/cell-types/purkinje-cells) in the [cerebellum](/brain-regions/cerebellum), particularly in the cerebellar vermis, with relative preservation of other brain structures[4](#1). [@dietary]

Genetics

Inheritance Pattern

SCA6 follows an autosomal dominant inheritance pattern with essentially complete penetrance[1](#1): [@retinal]

| Allele Type | CAG Repeat Count | Significance | [^6]
|---|---|---| [^7]
| Normal | 4-18 repeats | Non-pathogenic | [^8]
| Intermediate/Uncertain | 19-20 repeats | Uncertain penetrance | [^9]
| Pathogenic (full penetrance) | 20-33 repeats | Disease-causing | [^10]
| Most common pathogenic allele | 22 repeats | Typical expansion | [^11]

Unlike most other polyglutamine disorders such as [Huntington's disease](/mechanisms/huntington-pathway) or SCA1, SCA6 does not show significant intergenerational instability of the repeat. The CAG repeat expansions are relatively stable during transmission, so anticipation (earlier onset in successive generations) is generally not observed[5](#1). [^12]

The CACNA1A Gene

The CACNA1A gene encodes two distinct proteins through a bicistronic mechanism discovered in 2013[6](#1): [^13]

The polyglutamine tract expanded in SCA6 resides within the alpha-1ACT protein. When expanded, alpha-1ACT loses its transcription factor function and gains toxic properties[6](#1). [^14]

Allelic Disorders

SCA6 is one of four allelic disorders caused by mutations in CACNA1A: [^15]

| Disorder | Mutation Type | Key Features | [^16]
|---|---|---| [^17]
| SCA6 | CAG repeat expansion (20-33) | Late-onset progressive cerebellar ataxia | [^18]
| Episodic Ataxia Type 2 (EA2) | Loss-of-function mutations | Episodic ataxia; responds to acetazolamide |
| Familial Hemiplegic Migraine Type 1 (FHM1) | Gain-of-function missense | Hemiplegic migraine with or without ataxia |
| CACNA1A epileptic encephalopathy | Haploinsufficiency | Cognitive impairment, epilepsy, mild cerebellar signs |

Pathophysiology

SCA6 pathophysiology is multifaceted, involving at least three interrelated mechanisms[7](#1):

Calcium Channel Dysfunction

P/Q-type voltage-gated calcium channels are particularly abundant in cerebellar Purkinje cells and granule cells. The polyglutamine expansion in SCA6[8](#1):

• Shifts the voltage dependence of channel activation
• Alters the rate of channel inactivation
• Impairs normal G-protein regulation of P/Q-type channels
• Leads to excessive calcium ion entry into Purkinje cells, contributing to [excitotoxicity](/entities/excitotoxicity)

Polyglutamine Protein Aggregation

Despite the relatively small polyglutamine expansion (20-33 repeats, the smallest of any polyQ disorder), SCA6 exhibits toxic [protein aggregation](/mechanisms/protein-aggregation)[4](#1):

• Cytoplasmic aggregates of the C-terminal fragment containing the expanded polyQ tract accumulate in [Purkinje cells](/cell-types/purkinje-cells)
• The expanded alpha-1ACT transcription factor forms toxic aggregates
• Nuclear inclusions containing mutant protein are found in affected [neurons](/entities/neurons)

Transcriptional Dysregulation

The expanded alpha-1ACT protein fails to properly regulate expression of genes involved in Purkinje cell development and maintenance, contributing to progressive [neurodegeneration](/diseases/neurodegeneration). Recent research has also identified impaired [mitophagy](/mechanisms/mitophagy) in SCA6 Purkinje cells and reduced [BDNF](/proteins/bdnf-protein) signaling[9](#1).

Neuropathology

Postmortem studies reveal:

• Selective and marked degeneration of cerebellar [Purkinje cells](/cell-types/purkinje-cells)
• Atrophy most pronounced in the cerebellar vermis and flocculus
• Combined Purkinje cell and granule cell degeneration in some cases
• Evidence of trans-synaptic degeneration
• Relative preservation of brainstem and cerebral [cortex](/brain-regions/cortex)

Clinical Presentation

Core Features

SCA6 presents as a slowly progressive, predominantly cerebellar syndrome[3](#1):

Initial symptoms (in approximately 90% of cases): Gait unsteadiness, stumbling, and imbalance. In approximately 10%, dysarthria is the first symptom.

Core clinical features:

• Progressive gait ataxia
• Upper-limb incoordination and intention tremor
• Cerebellar dysarthria (slurred, scanning speech)

Oculomotor Abnormalities

Oculomotor dysfunction is a hallmark of SCA6:

• Horizontal gaze-evoked nystagmus (70-100% of patients)
• Downbeat vertical nystagmus (65-83%, highly characteristic)
• Diplopia and difficulty fixating on moving objects

Additional Features

• Dysphagia and choking (common in later stages)
• Hyperreflexia and extensor plantar responses (40-50%)
• Basal ganglia signs including dystonia and blepharospasm (up to 25%)
• Some patients initially present with episodic ataxia before progression

Preserved Functions

• Cognition is generally preserved (though mild cerebellar cognitive deficits are reported)
• Peripheral nerve function is mostly intact (79% show no neuropathy)

Disease Progression

SCA6 progresses more slowly than SCA1, SCA2, or [SCA3](/genes/sca3). The annual SARA (Scale for the Assessment and Rating of Ataxia) score increase is approximately 0.81 points per year. Most patients require wheelchair assistance by their sixties[10](#1).

Diagnosis

Clinical Suspicion

SCA6 should be suspected in individuals with adult-onset, slowly progressive cerebellar ataxia with prominent dysarthria and nystagmus (especially downbeat nystagmus), particularly with autosomal dominant family history.

Confirmatory Testing

Molecular genetic testing is the gold standard: PCR-based determination of CAG repeats in the CACNA1A gene. Finding 20 or more CAG repeats confirms the diagnosis[11](#1).

Neuroimaging

[MRI](/diagnostics/mri-neuroimaging) reveals essentially pure cerebellar atrophy, particularly of the cerebellar vermis, with the brainstem and cerebral hemispheres typically spared.

Differential Diagnosis

• Other autosomal dominant cerebellar ataxias (SCA1, SCA2, [SCA3](/genes/sca3)
• Episodic ataxia type 2 (allelic disorder, episodic rather than progressive)
• [multiple system atrophy](/diseases/multiple-system-atrophy), cerebellar type (MSA-C)
• Sporadic adult-onset ataxia of unknown etiology
• [Friedreich's Ataxia](/diseases/friedreichs-ataxia) (autosomal recessive)

Treatment

There is currently no disease-modifying therapy or cure for SCA6. Management is symptomatic and supportive[12](#1).

Symptomatic Treatments

• Acetazolamide: Beneficial for some patients, especially those with episodic ataxia-like presentations
• 4-Aminopyridine (fampridine): A potassium channel blocker that can improve nystagmus and oscillopsia symptoms
• Riluzole: Modest improvement in motor scores across hereditary ataxias

Supportive Management

• Physical therapy and rehabilitation for balance and mobility
• Occupational therapy for activities of daily living
• Speech therapy for dysarthria and dysphagia
• Assistive devices and fall prevention strategies

Investigational Therapies

• L-Arginine: A Phase 2 trial in Japan (2024) showed improvement of 0.96 SARA points; it inhibits conformational change and aggregation of polyQ proteins[13](#1)
• miRNA-mediated therapy: AAV9-delivered miR-3191-5p blocks IRES-driven translation of toxic alpha-1ACT, preventing ataxia and Purkinje cell degeneration in mice while preserving normal calcium channel function[14](#1)
• TrkB-Akt signaling restoration: Exercise and the TrkB agonist 7,8-dihydroxyflavone rescued motor coordination in SCA6 mice[9](#1)

Epidemiology

SCA6 prevalence varies significantly by geography due to founder effects[15](#1):

| Region | SCA6 as % of ADCA | Notes |
|---|---|---|
| Western Japan (Chugoku/Kansai) | Up to 31% | Strong founder effect |
| Germany | 13-22% | |
| United States | 12-15% | |
| South Korea | 7% | |
| United Kingdom | ~5% | Point prevalence 1.59/100,000 |
| France/Spain | 1-2% | |

The high prevalence in Western Japan, particularly around the Seto Inland Sea, is attributed to a founder effect. Global haplotype analysis suggests pathogenic expansions are associated with a common CACNA1A haplotype across populations worldwide[16](#1).

Current Research

Disease Models

• Rolling Nagoya mouse: Natural mutant with missense mutation in Cacna1a, used for drug testing
• SCA6 knock-in mice: Generated with varying CAG repeats (14Q, 30Q, 84Q), modeling human disease progression[17](#1)
• iPSC-derived neuronal models: Patient-derived [neurons](/entities/neurons) used to study bicistronic CACNA1A expression[18](#1)

Gene Therapy Approaches

• miRNA therapy targeting the CACNA1A second cistron (alpha-1ACT) selectively reduces the toxic protein while preserving essential calcium channel function[14](#1)
• Antisense oligonucleotides (ASOs): Preclinical work showing phenotype improvement
• FDA-approved drug repurposing: Screening for small molecules that selectively reduce polyQ-containing alpha-1ACT levels

See Also

• [Purkinje Cells](/cell-types/purkinje-cells)

External Links

• [GeneReviews: Spinocerebellar Ataxia Type 6](https://www.ncbi.nlm.nih.gov/books/NBK1140/)
• [OMIM #183086: Spinocerebellar Ataxia 6](https://omim.org/entry/183086)
• [National Ataxia Foundation](https://www.ataxia.org/)
• [Orphanet: Spinocerebellar Ataxia Type 6](https://www.orpha.net/en/disease/detail/98758)

Background

The study of Spinocerebellar Ataxia Type 6 (Sca6) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research (2024-2026)

This section highlights recent publications relevant to this disease.

• [Metformin improves RAN protein pathology, alternative splicing, and behavioral phenotypes in SCA8 mice.](https://pubmed.ncbi.nlm.nih.gov/41771688/) (2026 May) - Life science alliance
• [Cerebellar magnetic stimulation increased beta power and phase synchronisation in spinocerebellar ataxia type 3.](https://pubmed.ncbi.nlm.nih.gov/41707444/) (2026 Apr) - Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
• [Identification of a novel mutation in metabotropic glutamate receptor 1 causing autosomal recessive spinocerebellar ataxia-13 in a Pakistani family.](https://pubmed.ncbi.nlm.nih.gov/41649149/) (2026 Apr 1) - Clinical dysmorphology
• [Dietary restriction mitigates cognitive impairments in a mouse model of SCA19/22.](https://pubmed.ncbi.nlm.nih.gov/41554439/) (2026 Apr) - Mechanisms of ageing and development
• [Retinal morphology in spinocerebellar ataxia type 1 (SCA1) mice: A stereological analysis across different age groups.](https://pubmed.ncbi.nlm.nih.gov/41548833/) (2026 Apr) - Experimental eye research

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data

References